These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

429 related articles for article (PubMed ID: 29051030)

  • 21. Outcome of metastatic urothelial carcinoma treated by systemic chemotherapy: Prognostic factors based on real-world clinical practice in Japan.
    Abe T; Ishizaki J; Kikuchi H; Minami K; Matsumoto R; Harabayashi T; Sazawa A; Mochizuki T; Chiba S; Akino T; Murakumo M; Miyajima N; Tsuchiya K; Maruyama S; Murai S; Shinohara N
    Urol Oncol; 2017 Feb; 35(2):38.e1-38.e8. PubMed ID: 27693091
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Optimal Number of Cycles of First-line Platinum-based Chemotherapy for Metastatic Urothelial Carcinoma.
    Minato A; Ohno D; Murooka K; Okumura Y; Takaba T; Higashijima K; Nagata Y; Tomisaki I; Harada K; Fujimoto N
    In Vivo; 2024; 38(4):1927-1934. PubMed ID: 38936900
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Prognostic significance of CT-determined sarcopenia in patients with advanced gastric cancer.
    Lee JS; Kim YS; Kim EY; Jin W
    PLoS One; 2018; 13(8):e0202700. PubMed ID: 30125312
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Weighing the role of skeletal muscle mass and muscle density in cancer patients receiving PD-1/PD-L1 checkpoint inhibitors: a multicenter real-life study.
    Cortellini A; Bozzetti F; Palumbo P; Brocco D; Di Marino P; Tinari N; De Tursi M; Agostinelli V; Patruno L; Valdesi C; Mereu M; Verna L; Lanfiuti Baldi P; Venditti O; Cannita K; Masciocchi C; Barile A; McQuade JL; Ficorella C; Porzio G
    Sci Rep; 2020 Jan; 10(1):1456. PubMed ID: 31996766
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Clinical impact of postoperative loss in psoas major muscle and nutrition index after radical cystectomy for patients with urothelial carcinoma of the bladder.
    Miyake M; Morizawa Y; Hori S; Marugami N; Shimada K; Gotoh D; Tatsumi Y; Nakai Y; Inoue T; Anai S; Torimoto K; Aoki K; Tanaka N; Fujimoto K
    BMC Cancer; 2017 Mar; 17(1):237. PubMed ID: 28359307
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Impact of the Number of Cycles of Platinum Based First Line Chemotherapy for Advanced Urothelial Carcinoma.
    Sonpavde GP; Mariani L; Lo Vullo S; Raggi D; Giannatempo P; Bamias A; Crabb SJ; Bellmunt J; Yu EY; Niegisch G; Vaishampayan UN; Theodore C; Berthold DR; Srinivas S; Sridhar SS; Plimack ER; Rosenberg JE; Powles T; Galsky MD; Necchi A
    J Urol; 2018 Dec; 200(6):1207-1214. PubMed ID: 30012366
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Impact of Prior Platinum-Based Therapy on Patients Receiving Salvage Systemic Treatment for Advanced Urothelial Carcinoma.
    Sonpavde G; Pond GR; Di Lorenzo G; Buonerba C; Rozzi A; Lanzetta G; Necchi A; Giannatempo P; Raggi D; Matsumoto K; Choueiri TK; Mullane S; Niegisch G; Albers P; Lee JL; Kitamura H; Kume H; Bellmunt J
    Clin Genitourin Cancer; 2016 Dec; 14(6):494-498. PubMed ID: 27262369
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Third-Line Chemotherapy for Metastatic Urothelial Cancer: A Retrospective Observational Study.
    Di Lorenzo G; Buonerba C; Bellelli T; Romano C; Montanaro V; Ferro M; Benincasa A; Ribera D; Lucarelli G; De Cobelli O; Sonpavde G; De Placido S
    Medicine (Baltimore); 2015 Dec; 94(51):e2297. PubMed ID: 26705213
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A Phase II Study of Weekly Docetaxel as Second-Line Chemotherapy in Patients With Metastatic Urothelial Carcinoma.
    Kim YS; Lee SI; Park SH; Park S; Hwang IG; Lee SC; Sun JM; Lee J; Lim HY
    Clin Genitourin Cancer; 2016 Feb; 14(1):76-81. PubMed ID: 26454620
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Computed Tomography-assessed Skeletal Muscle Index and Skeletal Muscle Radiation Attenuation in Patients With Ovarian Cancer Treated With Primary Surgery Followed by Platinum-based Chemotherapy: A Single-center Italian Study.
    Gadducci A; Simonetti E; Mezzapesa F; Cosio S; Miccoli M; Frey J; Tintori R; Bulleri A; Neri E
    Anticancer Res; 2022 Feb; 42(2):947-954. PubMed ID: 35093894
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Prognostic significance of sarcopenia in upper tract urothelial carcinoma patients treated with radical nephroureterectomy.
    Fukushima H; Nakanishi Y; Kataoka M; Tobisu K; Koga F
    Cancer Med; 2016 Sep; 5(9):2213-20. PubMed ID: 27350148
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Skeletal muscle mass is an imaging biomarker for decreased survival in patients with oropharyngeal squamous cell carcinoma.
    Chargi N; Bril SI; Swartz JE; Wegner I; Willems SM; de Bree R
    Oral Oncol; 2020 Feb; 101():104519. PubMed ID: 31855705
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Five-Factor Prognostic Model for Survival of Post-Platinum Patients with Metastatic Urothelial Carcinoma Receiving PD-L1 Inhibitors.
    Sonpavde G; Manitz J; Gao C; Tayama D; Kaiser C; Hennessy D; Makari D; Gupta A; Abdullah SE; Niegisch G; Rosenberg JE; Bajorin DF; Grivas P; Apolo AB; Dreicer R; Hahn NM; Galsky MD; Necchi A; Srinivas S; Powles T; Choueiri TK; Pond GR
    J Urol; 2020 Dec; 204(6):1173-1179. PubMed ID: 32552295
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Skeletal Muscle Attenuation (Sarcopenia) Predicts Reduced Overall Survival in Patients with Advanced Epithelial Ovarian Cancer Undergoing Primary Debulking Surgery.
    Ataseven B; Luengo TG; du Bois A; Waltering KU; Traut A; Heitz F; Alesina PF; Prader S; Meier B; Schneider S; Koch JA; Walz M; Groeben HT; Nina P; Brunkhorst V; Heikaus S; Harter P
    Ann Surg Oncol; 2018 Oct; 25(11):3372-3379. PubMed ID: 30069659
    [TBL] [Abstract][Full Text] [Related]  

  • 35. No influence of sarcopenia on survival of ovarian cancer patients in a prospective validation study.
    Ubachs J; Koole SN; Lahaye M; Fabris C; Bruijs L; Schagen van Leeuwen J; Schreuder HWR; Hermans RH; de Hingh IH; van der Velden J; Arts HJ; van Ham M; van Dam P; Vuylsteke P; Bastings J; Kruitwagen RFPM; Lambrechts S; Olde Damink SWM; Rensen SS; Van Gorp T; Sonke GS; van Driel WJ
    Gynecol Oncol; 2020 Dec; 159(3):706-711. PubMed ID: 33019981
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Prognostic significance of serum γ-glutamyltransferase in patients with advanced urothelial carcinoma.
    Takemura K; Fukushima H; Ito M; Kataoka M; Nakanishi Y; Sakamoto K; Suzuki H; Tobisu KI; Koga F
    Urol Oncol; 2019 Feb; 37(2):108-115. PubMed ID: 30478012
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Prognostic Effect of FGFR Mutations or Gene Fusions in Patients with Metastatic Urothelial Carcinoma Receiving First-line Platinum-based Chemotherapy: Results from a Large, Single-institution Cohort.
    Necchi A; Lo Vullo S; Raggi D; Gloghini A; Giannatempo P; Colecchia M; Mariani L
    Eur Urol Focus; 2019 Sep; 5(5):853-856. PubMed ID: 29525380
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Skeletal muscle depletion is an independent prognostic factor for hepatocellular carcinoma.
    Iritani S; Imai K; Takai K; Hanai T; Ideta T; Miyazaki T; Suetsugu A; Shiraki M; Shimizu M; Moriwaki H
    J Gastroenterol; 2015 Mar; 50(3):323-32. PubMed ID: 24817668
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Low Skeletal Muscle Mass Is a Risk Factor for Aspiration Pneumonia During Chemoradiotherapy.
    Endo K; Ueno T; Hirai N; Komori T; Nakanishi Y; Kondo S; Wakisaka N; Yoshizaki T
    Laryngoscope; 2021 May; 131(5):E1524-E1529. PubMed ID: 33030229
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Excision repair cross-complementation group 1 (ERCC1) expression in advanced urothelial carcinoma patients receiving cisplatin-based chemotherapy.
    Kim KH; Do IG; Kim HS; Chang MH; Kim HS; Jun HJ; Uhm J; Yi SY; Lim DH; Ji SH; Park MJ; Lee J; Park SH; Kwon GY; Lim HY
    APMIS; 2010 Dec; 118(12):941-8. PubMed ID: 21091775
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 22.